EndoExpertHub

Endo 2026 Post Conference Updates will feature expert commentary and discussion led by Zehra Tekin, MD, Felona Gunawan, MD, and Sadia Ali, MD. This program will highlight key clinical and scientific advances presented at ENDO 2026, focusing on the latest research, evidence-based management strategies, and emerging therapies across the spectrum of endocrinology, diabetes, metabolism, and hormone-related disorders. The session will provide in-depth analysis of late-breaking abstracts, landmark clinical trial updates, and evolving treatment approaches, with faculty drawing on their expertise to contextualize these findings for clinical practice. Attendees will gain an understanding of emerging standards of care, innovative therapeutic developments, and important areas of ongoing research presented at ENDO 2026. Through expert discussion and practical clinical perspectives, Endo 2026 Post Conference Updates will serve as a concise, high-yield review for clinicians, trainees, and researchers seeking to incorporate the most impactful discoveries from ENDO 2026 into their clinical practice and scholarly activities.

R. Michael Tuttle, MD is a Professor of Medicine at Weill Medical College of Cornell University and serves as Chief of the Endocrinology Service at Memorial Sloan Kettering Cancer Center in New York City. His clinical practice is devoted entirely to the evaluation and management of patients with thyroid cancer, with a particular emphasis on cases involving aggressive disease and complex management challenges. R. Michael Tuttle, MD earned his medical degree from the University of Louisville School of Medicine and completed his residency at Dwight David Eisenhower Army Medical Center, followed by a fellowship at Madigan Army Medical Center. He is board-certified in Endocrinology and Metabolism. R. Michael Tuttle, MD's research is centered on the management of thyroid cancer, with particular focus on individualized risk stratification and the rational tailoring of therapy to patient-specific outcomes. He designed and validated the first real-time risk assessment model for thyroid cancer management, in which individual risk estimates are updated over time based on response to initial therapy. His ongoing investigations address the risk of recurrence and disease-specific mortality in individual patients, the appropriate role of active surveillance in low-risk papillary thyroid cancer, and the application of minimalistic management strategies to reduce overtreatment. His earlier clinical studies also helped define the role of recombinant human TSH as an adjuvant for radioactive iodine therapy in both low- and high-risk patients, including those with radioactive iodine-avid distant metastases. In addition to his clinical and research contributions, R. Michael Tuttle, MD is a prolific academic author with more than 460 research works and over 54,000 citations to his credit. He has been repeatedly recognized by Castle Connolly as one of America's Top Doctors, with distinctions spanning more than a decade, and is consistently listed among New York Metro Area's Top Doctors.

Abhimanyu Garg, M.D. is a Professor of Internal Medicine in the Division of Endocrinology at UT Southwestern Medical Center in Dallas, Texas, where he also serves as Director of Metabolic Diseases in the Center for Human Nutrition, Director of the Nutrition and Metabolic Diseases Fellowship Program, and holder of the Distinguished Chair in Human Nutrition Research. His clinical practice is devoted to the evaluation and management of patients with lipodystrophy, lipid metabolism disorders, and related metabolic diseases. Abhimanyu Garg, M.D. earned his medical degree and completed his residency in internal medicine at the All India Institute of Medical Sciences. He subsequently completed fellowship training in endocrinology and metabolism at the University of Alabama at Birmingham and at UT Southwestern, where he joined the faculty in 1988. Abhimanyu Garg, M.D. is widely regarded as the leading global authority on lipodystrophy research and treatment, having devoted nearly three decades to advancing the understanding and management of these rare disorders. He was the first investigator to evaluate leptin as a therapeutic option for lipodystrophy through a clinical trial launched at UT Southwestern in 2000, work that directly contributed to the FDA's 2014 approval of metreleptin for the treatment of generalized lipodystrophy. His ongoing research focuses on whether leptin therapy can improve metabolic outcomes in hypoleptinemic patients with partial lipodystrophies. In addition to his clinical and research contributions, Abhimanyu Garg, M.D. is a recipient of the Jean D. Wilson, M.D. Award for excellence in scientific mentorship in the Division of Endocrinology and Metabolism at UT Southwestern. He holds membership in the American Diabetes Association, the Endocrine Society, the American Society of Human Genetics, and the Association of Specialty Professors, among other professional organizations.